OptiNose Investor Relations Material

OptiNose Inc. is a pharmaceutical company engaged in the development and commercialization of innovative products for patients under the care of ear, nose, throat, and allergy specialists in the United States. The company has developed a proprietary Exhalation Delivery Systems, a novel drug delivery concept that facilitates broad, consistent drug delivery deep within the nasal passages. This technology aims to leverage the mucosal surfaces as a potential target for treating both local and systemic diseases. OptiNose's portfolio includes XHANCE, a therapeutic product utilizing EDS to deliver a topically acting corticosteroid for the treatment of chronic rhinosinusitis with nasal polyps. Additionally, the company has developed Onzetra Xsail, a powder EDS device, and is exploring further applications of its technology in various clinical trials. OptiNose is headquartered in Yardley, Pennsylvania, and its shares are listed on the NASDAQ.